vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Sachem Capital Corp. (SACH). Click either name above to swap in a different company.
Sachem Capital Corp. is the larger business by last-quarter revenue ($12.0M vs $10.7M, roughly 1.1× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 8.3%, a 15.2% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -18.8%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -13.4%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
ABUS vs SACH — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $12.0M |
| Net Profit | $2.5M | $997.0K |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -3.1% |
| Net Margin | 23.5% | 8.3% |
| Revenue YoY | 522.2% | -18.8% |
| Net Profit YoY | 112.7% | 119.7% |
| EPS (diluted) | $0.01 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $12.0M | ||
| Q2 25 | $10.7M | $10.8M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $10.8M | ||
| Q3 24 | — | $14.8M | ||
| Q2 24 | — | $15.1M | ||
| Q1 24 | — | $16.8M | ||
| Q4 23 | $2.1M | $16.0M |
| Q3 25 | — | $997.0K | ||
| Q2 25 | $2.5M | $1.9M | ||
| Q1 25 | — | $904.0K | ||
| Q4 24 | — | $-36.1M | ||
| Q3 24 | — | $-5.1M | ||
| Q2 24 | — | $-3.1M | ||
| Q1 24 | — | $4.7M | ||
| Q4 23 | — | $-1.1M |
| Q3 25 | — | -3.1% | ||
| Q2 25 | 13.9% | 9.9% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | -131.1% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | — | -20.6% | ||
| Q1 24 | — | 25.4% | ||
| Q4 23 | -967.2% | — |
| Q3 25 | — | 8.3% | ||
| Q2 25 | 23.5% | 17.5% | ||
| Q1 25 | — | 7.9% | ||
| Q4 24 | — | -335.6% | ||
| Q3 24 | — | -34.2% | ||
| Q2 24 | — | -20.2% | ||
| Q1 24 | — | 27.8% | ||
| Q4 23 | — | -6.9% |
| Q3 25 | — | $0.00 | ||
| Q2 25 | $0.01 | $0.02 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-0.13 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $0.08 | ||
| Q4 23 | $-0.12 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $12.6M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $175.6M |
| Total Assets | $103.3M | $484.4M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $12.6M | ||
| Q2 25 | $37.4M | $23.5M | ||
| Q1 25 | — | $25.8M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | — | $7.4M | ||
| Q2 24 | — | $12.4M | ||
| Q1 24 | — | $56.8M | ||
| Q4 23 | $126.0M | $50.4M |
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | $230.2M | ||
| Q4 24 | — | $230.2M | ||
| Q3 24 | — | $264.7M | ||
| Q2 24 | — | $264.7M | ||
| Q1 24 | — | $288.4M | ||
| Q4 23 | $0 | $288.4M |
| Q3 25 | — | $175.6M | ||
| Q2 25 | $83.0M | $177.9M | ||
| Q1 25 | — | $179.3M | ||
| Q4 24 | — | $181.7M | ||
| Q3 24 | — | $220.6M | ||
| Q2 24 | — | $230.2M | ||
| Q1 24 | — | $237.4M | ||
| Q4 23 | $106.0M | $230.1M |
| Q3 25 | — | $484.4M | ||
| Q2 25 | $103.3M | $501.8M | ||
| Q1 25 | — | $491.4M | ||
| Q4 24 | — | $492.0M | ||
| Q3 24 | — | $555.5M | ||
| Q2 24 | — | $586.3M | ||
| Q1 24 | — | $626.5M | ||
| Q4 23 | $144.4M | $620.9M |
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 1.21× | ||
| Q4 23 | 0.00× | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $4.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | 4.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.9M | ||
| Q2 25 | $-15.7M | $501.0K | ||
| Q1 25 | — | $191.0K | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $7.0M | ||
| Q1 24 | — | $4.2M | ||
| Q4 23 | $-17.3M | $2.9M |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.0% | — |
| Q3 25 | — | 4.95× | ||
| Q2 25 | -6.24× | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.90× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
